PCVX

Vaxcyte's stock has been influenced by several key events over the past six months. In February 2026, the company reported financial results, advanced its VAX-31 program, and completed an equity offering. In March 2026, positive VAX-31 Phase 1/2 data was published, and enrollment in OPUS-1 and OPUS-2 Phase 3 trials was completed. In April 2026, Wall Street Zen downgraded the stock to "strong sell," while other analysts maintained a "Moderate Buy" consensus, and the company reported quarterly EPS that missed estimates. In May 2026, Q1 2026 financial results were reported, highlighting the completion of enrollment across all three adult Phase 3 OPUS trials, and despite a strong cash position, the stock tumbled due to a widening net loss and increased R&D expenses, though it saw some gains earlier in the month.